Key result
Calcium antagonists preserved or improved renal function in short-term studies, but long-term clinical trials are required to confirm sustained protection.
Why the study?
Do calcium antagonists protect the human kidney from systemic and glomerular hypertension in patients with essential hypertension and advanced renal parenchymal disease?
Do calcium antagonists protect the human kidney from systemic and glomerular hypertension in patients with essential hypertension and advanced renal parenchymal disease?
Short-term data suggest calcium antagonists may preserve renal function in hypertensive patients, but long-term clinical trials are necessary to confirm renoprotective effects.
Answers are grounded in this paper and cite their sources.
Short-term renal preservation data should not alter prescribing; leaves open whether calcium antagonists confer sustained renoprotection in essential hypertension.
The natural course of essential hypertension, and hypertension associated with advanced renal parenchymal disease, is characterized by a progressive deterioration of renal function. If calcium antagonists can control both systemic and glomerular hypertension, they may be able to attenuate this process. Short-term studies in our laboratory suggest that the calcium antagonists amlodipine, diltiazem, and nifedipine preserve and/or improve renal function; there were no adverse effects on glomerular filtration, effective renal plasma flow, and/or urinary protein excretion. However, long-term clinical trials are required to determine if the observed short-term renal responses are sustained and if calcium antagonists protect the human kidney from systemic and glomerular hypertension.
No takes yet. Share an insight, caveat, or question.
Bauer et al. (1989) conducted a review in Essential hypertension and hypertension associated with advanced renal parenchymal disease. Calcium antagonists (amlodipine, diltiazem, nifedipine) was evaluated on Renal function (glomerular filtration, effective renal plasma flow, urinary protein excretion). Calcium antagonists preserved or improved renal function in short-term studies, but long-term clinical trials are required to confirm sustained protection.
Synapse has enriched 10 related papers. Consider them for comparative context: